NAMs: What’s Actually Validated, and What’s Just Hype

Posted on July 16, 2026

New Approach Methodologies are having a moment. The hard part isn’t believing they’re coming. It’s telling the validated tools from the ones that are still a promise.

If you follow the trade press at all, you can’t miss it. New Approach Methodologies, or NAMs, are suddenly everywhere: organ-on-a-chip, in-vitro assays, AI toxicity models, all framed as the thing that finally replaces the animal study. For anyone who runs a vivarium or signs off on a study design, it lands as a fair question and a slightly uneasy one: is my work about to change, and how much of this is real?

Some of it is very real. In April 2025 the FDA announced a plan to phase out its animal-testing requirement for monoclonal antibodies and other drugs, starting with a pilot program and a multi-year roadmap that leans on computational models and human-relevant lab systems. That’s not a press release from a startup. That’s the regulator telling developers they can start submitting NAM data in place of certain animal studies.

The word doing all the work is “validated”

Here’s where the signal gets muddy. “NAM” covers everything from a method with an adopted international test guideline to a device that looked promising in one lab’s hands last year. Lumping them together is how a genuinely useful shift turns into hype.

It helps to think of any given method as sitting somewhere on a spectrum. On one end sits the validated and formally accepted: a regulator will take the data instead of the animal result, today, for a defined purpose. In the middle sits the promising and in qualification: strong published performance, real interest from agencies, but not yet a drop-in replacement. On the far end sits the aspirational, a real idea that isn’t a decision-ready tool yet. The trouble is that all three get called “NAMs” in the same sentence, and a headline rarely tells you which one it’s describing.

Three lab flasks under decreasing light: the left brightly lit and glowing green (validated), the middle half-lit (in qualification), the right faint and dissolving into the dark (aspirational)

What’s actually validated today

The clearest example of the real end of the spectrum is skin sensitisation. In 2021 the OECD adopted Guideline 497 on Defined Approaches for Skin Sensitisation, the first internationally harmonised non-animal approach that can replace an animal test for a specific hazard. It combines in-chemico, in-vitro and in-silico inputs through a fixed data-interpretation procedure, and against curated human data it predicts sensitisation at least as well as the mouse Local Lymph Node Assay it stands in for. That’s what “validated” actually looks like: a named guideline, a defined endpoint, and regulatory acceptance you can point to.

Now compare that to organ-on-a-chip, the poster child for the whole movement. The data are genuinely encouraging. In a 2022 study in Communications Medicine, an Emulate human Liver-Chip tested against a blinded set of 27 drugs correctly flagged 87% of the compounds that caused drug-induced liver injury in people, at 100% specificity, including drugs that had cleared animal testing before hurting patients. Impressive, and exactly why the FDA is interested. But a strong performance paper is not the same as an adopted test guideline. Liver-chips today are largely a weight-of-evidence tool used alongside existing studies, not a stamped replacement for them. Same technology, very different place on the spectrum.

Same field, different place on the spectrum
Skin-sensitisation Defined Approach
OECD Guideline 497		 Human Liver-Chip
organ-on-a-chip
Where on the spectrum Validated & accepted Promising, in qualification
Regulatory status Adopted international test guideline (OECD 497, 2021) No adopted test guideline yet
Role today Can replace the mouse test for that endpoint Weight-of-evidence, used alongside animal studies
Evidence Predicts at least as well as the animal test on curated human data Caught 87% of liver-injury drugs at 100% specificity (27-drug blinded set)
Replace an animal test today? Yes, for the defined endpoint Not yet, as a stamped replacement
Same organ-on-a-chip technology can be genuinely exciting and still not be a validated replacement. Validation is endpoint-by-endpoint.

What it means for your lab

The practical move is to stop reacting to the category and start asking about the specific endpoint in front of you. A method that replaces an animal test for skin sensitisation tells you nothing about whether you can drop a repeat-dose toxicity study. Validation is endpoint-by-endpoint and context-by-context, and the honest answer for most safety endpoints in 2026 is still “not yet, but the data are being built.”

For most facilities, the near-term reality is augmentation, not replacement. NAM data increasingly rides alongside animal work as supporting evidence, and the animal studies that remain aren’t going anywhere quietly. If you’re in the monoclonal-antibody space, the FDA pilot is worth tracking closely, because that’s where the first real substitutions are being negotiated. Everywhere else, the useful posture is to watch which guidelines get adopted for the endpoints you actually run, and to be skeptical of any claim that treats “NAM” as a synonym for “approved.”

A wordless diagram: an organ-on-a-chip and an animal study (a cage with a data-matrix ID tag) both feeding via arrows into a single combined evidence dossier marked with a checkmark — NAM data augmenting animal work rather than replacing it.

The takeaway

NAMs are not hype, and they’re not a clean sweep either. They’re a fast-moving field where a handful of methods have earned genuine regulatory acceptance and a great many more are somewhere on the way. The people who navigate this well won’t be the ones who believed the technology fastest. They’ll be the ones who learned to ask, every time, “validated for what, and accepted by whom?” They could tell the difference between a test guideline and a good demo.

Where we sit on this. Full disclosure: RapID Lab makes tools for identifying research animals, so a shift away from animal studies isn’t a neutral topic for us. Arguably it cuts against our own corner. We’d rather be straight about the field than defensive about it. Animal studies will be part of drug development for years yet, and while they are, doing them with clean, human-relevant data still matters. The same logic that makes a NAM credible (rigor you can point to) is the logic that should govern the animal work that remains.

References

  1. U.S. Food and Drug Administration. “FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs.” FDA News, April 2025. fda.gov
  2. OECD. “Guideline No. 497: Defined Approaches on Skin Sensitisation.” OECD Publishing, 2021 (updated 2025). oecd.org
  3. Ewart, L., Apostolou, A., Briggs, S. A., et al. “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology.” Communications Medicine 2, 154 (2022). ncbi.nlm.nih.gov

About RapID Lab. RapID Lab makes minimally invasive, automated 2D-barcode ear tags for identifying rodents in preclinical research. We’re a small team in San Francisco focused on accurate, low-stress animal identification. rapidlab.com

This article is for general informational purposes and reflects RapID Lab’s perspective on industry practice. It is not regulatory advice, and it is not a substitute for your facility’s SOPs or current agency guidance.